A Dose Titration of Droxidopa in Patients With Spinal Cord Injury

Summary

The investigators seek to determine the efficacy, duration of action and safety of escalating dose of droxidopa on systemic blood pressure, cerebral blood flow and vasoactive hormones and catecholamines during upright seated posture. Primary Question: 1\. What is the lowest dose of droxidopa that increases seated SBP to 115±5 mmHg in men and 105±5 mmHg in women? * When does the defined increase in SBP occur after oral ingestion of droxidopa? * How long does this dose of droxidopa sustain SBP at these levels? * What are the vital signs and the subjective symptomology following droxidopa administration? Secondary Question: 1\. What is the MFV response to droxidopa administration in hypotensive individuals with SCI? * Does an increase in SBP correspond to an increase in MCA MFV? Tertiary Question: 1\. What is the vasoactive hormone and catecholamine response to droxidopa administration in hypotensive individuals with SCI? * Does droxidopa administration result in a change in APR, Aldo or NE in hypotensive individuals with SCI?

Timeline

Start

2011-05

Primary completion

2013-05

Completion

2013-05

Drugs

Indications